Lyra Therapeutics, Inc. announced the appointment of Ann Merrifield to its Board of Directors. Ms. Merrifield is an accomplished leader in the life science industry with more than 30 years of experience primarily focused on building commercial biotechnology businesses. Ann Merrifield is an experienced business leader with proven capability in developing high-growth, global biotechnology businesses, including physician-administered drugs and biologics, diagnostic services, and therapeutic devices. She has deep experience building effective organizations and developing strategies for profitable growth through sales and marketing optimization, strategic transactions, and pipeline development. She currently serves as a director for a portfolio of public and private companies in the life sciences sector. Previously, she spent an 18-year career at Genzyme Corporation, a diversified global biotechnology company.